相关实验视频

Updated: May 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

对于患有转移性EGFR阳性NSCLC的人来说,获得诊断和治疗:从项目PRIORITY中吸取教训

Jill Feldman¹, Ivy Elkins¹, Zofia Piotrowska²

¹EGFR Resisters, Deerfield, Illinois.

JTO clinical and research reports

|February 25, 2025

概括

这项研究强调了EGFR突变 (表皮生长因子受体突变) 非小细胞肺癌 (NSCLC) 的患者经验. 它揭示了在获得先进的诊断和治疗方法,如 osimertinib 的差异,即使在指导方针建议后.

科学领域:

在瘤学瘤学.
患者报告的结果
基因组医学是基因组医学.

背景情况:

对于EGFR突变 (EGFR-m) NSCLC的治疗环境已经发生了显著的变化.
有限的自我报告数据存在于EGFR-m NSCLC患者的生活经验.
项目 PRIORITY 是一项以患者为导向的研究,旨在解决这一差距.

研究的目的:

描述EGFR-m肺癌患者的临床特征和治疗经验.
探索患者对EGFR-m NSCLC中氨酸激酶抑制剂 (TKI) 时代的看法.
识别诊断和治疗准入方面的差异.

主要方法:

在线调查向EGFR抗体社区 (2019年4月 - 2020年1月) 分发.
调查捕获了人口统计,风险因素,诊断和治疗途径以及副作用.
使用了描述性统计数据,根据住院和癌症阶段对子组进行了分析.

主要成果:

425名参与者:大多数女性 (67%),60岁以下 (53%),美国人 (74%).
89%的人至少获得了一次TKI; osimertinib是第四阶段最常见的第一线TKI.
美国参与者更容易获得先进的诊断和较新的治疗方法; 47%的患者经历了疾病进展.

结论:

这项研究是首次探索患者对EGFR-m NSCLC的TKI时代的观点.
患者可以有效地自我报告有关肺癌的复杂健康信息.
鉴定出了治疗机会的差异,尽管指南对新疗法提出了建议.

关键词:

在EGFR的突变中.在NSCLCLC中,我们可以看到.非小细胞肺癌是什么?在线调查调查在线调查患者的体验患者的体验治疗方法治疗方法

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...